Immune complex-mediated neutrophil activation in patients with polymyalgia rheumatica.

"Disclosure statement : D.M. received Advisory Board fees from ChemoCentryx. C.L. received research funding from Exagen Inc., Pfizer, Gilead Sciences, Horizon Therapeutics, Amytryx, Redd Pharma and Eli Lilly. C.L. is a Scientific Advisory Board member at Redd Pharma."

"Funding This work was supported by the NIH training grant award #5T32HL007028-44 (D.M.) and the NIH grants 1R21EY029391 (C.L.) and R21AR075129 (C.L.). Disclosure statement: D.M. received Advisory Board fees from ChemoCentryx. C.L. received research funding from Exagen Inc., Pfizer, Gilead Sciences, Horizon Therapeutics, Amytryx, Redd Pharma and Eli Lilly. C.L. is a Scientific Advisory Board member at Redd Pharma. Patient consent for publication: Informed written consent was obtained from all participants in accordance with the Helsinki Declaration. Ethics approval: The study was approved by the regional ethics board at University of Washington, Seattle, WA (#3100) and Ethics Committee at Umea University, Sweden (§192/96, dnr 96-138)."